Lu­pus drug de­vel­op­ment mar­ket heat­ing up, while FDA links with ad­vo­ca­cy group to fur­ther ac­cel­er­ate re­search

The long-un­der­served sys­temic lu­pus ery­the­mato­sus (SLE) mar­ket is sud­den­ly buzzing with treat­ment pos­si­bil­i­ties. Less than two years af­ter As­traZeneca’s ap­proval for Saph­ne­lo — the first new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER